Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 255-264

  Radujkovic, Aleksandar ^a   Fruehauf, Stefan ^b   Zeller, W Jens ^c   Ho, Anthony D ^a   Topaly, Julian ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Center for Tumor Diagnostics and Therapy   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

BCR ABL; Combination treatment; Imatinib resistance; Nilotinib; Synergism

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IMATINIB; MITOXANTRONE; NILOTINIB; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; POINT MUTATION; PRIORITY JOURNAL; CELL STRAIN K 562; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; PIPERAZINES; PYRIMIDINES;

EID: 77953045617     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1158-7     Document Type: Article

References (47)

1. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science. 132:1497-1501
2. Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:290-293
3. Goldman JM, Melo JV (2003) Chronic myeloid leukemia - Advances in biology and new approaches to treatment. N Engl J Med 349:1451-1464
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1079-1082
5. Peggs K, Mackinnon S (2003) Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048-1050
6. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653
7. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST571: diverse mechanisms of resistance. Blood 96:1070-1079
8. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880
9. von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCRABL gene mutations in relation to clinical resistance of Philadelphia- chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487-491
10. Hochhaus A, Erben P, Ernst T, Mueller MC (2007) Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 44:15-24
11. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129-141 (erratum in Cancer Cell 2005;7:399)
12. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11:4941-4947
13. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551
14. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 110:3540-3546
15. Giles FJ, Larson RA, Kantarjian HM, le Coutre P, Baccarani M, Haque A, Gallagher N, Ottmann OG (2007) Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood 110:1025 (abstract)
16. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207-3213 (Pubitemid 46572505)
17. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Vernant JP, Bosi A et al (1993) Bone marrow transplantation for chronic myeloid leukemia: longterm results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transpl 12:509-516 (Pubitemid 23328366)
18. Topaly J, Zeller WJ, Fruehauf S (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 15:342-347
19. Topaly J, Fruehauf S, Ho AD, Zeller WJ (2002) Rationale for combination therapy of chronic myelogenous leukaemia with imatiniband irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 86:1487-1493
20. Topaly J, Zeller WJ, Fruehauf S (2002) Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 119:3-14
21. Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG. Leukemia 19:1198-1206
22. Radujkovic A, Topaly J, Fruehauf S, Zeller WJ (2006) Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. Anticancer Res 26:2169-2177
23. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ (2000) EYcacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195-3199
24. Liu WM, Stimson LA, Joel SP (2002) The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. Br J Cancer 86:1472-1478
25. Marley SB, Davidson RJ, Goldman JM, Gordon MY (2002) Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol 116:162-165
26. Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E (2007) Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Exp Oncol 29:126-131
27. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007
28. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J (2006) Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108:1328-1333
29. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
30. Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Müller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A (2007) Imatinib combined with mitoxantrone/ etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 109:1543-1549
31. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66:11314-11322
32. Michieli M, Michelutti A, Damiani D, Ermacora A, Masolini P, Stocchi R, Russo D (2001) Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines. Leuk Lymphoma 42:721-729
33. Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS (2003) Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone- refractory prostate cancer. Cancer Chemother Pharmacol 51:297-305
34. Takara K, Sakaeda T, Okumura K (2006) An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12:273-286
35. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G et al (1994) Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8:465-475
36. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, DellaGatta JL, Kung AL, Griffin JD (2007) Beneficial effects of combining nilotinib and imatinib in preclinical models of BCRABL+ leukemias. Blood 109:2112-2120
37. Hochhaus A, La Rosée P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18:1321-1331
38. Pieters R, Huismans DR, Leyva A, Veerman AJ (1988) Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett 41:323-332
39. Chow KU, Nowak D, Trepohl B, Hochmuth S, Schneider B, Hoelzer D, Mitrou PS, Bergmann L, Ottmann OG, Boehrer S (2007) The tyrosine kinase inhibitor AMN107 (nilotinib) exhibits off-target effects in lymphoblastic cell lines. Leuk Lymphoma. 48:1379-1388
40. Palacios R, Steinmetz M (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41:727-734
41. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 78:153-161
42. Zhou L, Meng F, Yin O, Wang J, Wang Y, Wei Y, Hu P, Shen Z (2009) Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther. 31:1568-1575
43. Feldman E, Lancet J, Kolitz JE, Trang JM, Mayer L, Louie AC (2009) Pharmacology of CPX-351: a nano-scale liposomal fixed molar ratio cytarabine-daunorubicin for patients with advanced leukemia. Haematologica 94(Suppl 2):67 (abstract 0174)
44. Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, Bugat R (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res 53:4850-4854
45. Kato Y, Nishimura S, Sakura N, Ueda K (2003) Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int 45:74-79
46. Spriggs DR, Robbins G, Arthur K, Mayer RJ, Kufe D (1988) Prolonged high dose ARA-C infusions in acute leukemia. Leukemia. 2:304-306
47. Giles FJ, le Coutre P, Bhalla KN, Ossenkoppele G, Alimena G, Haque A, Neil Gallagher N, Kantarjian HM (2007) Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC). Blood 110:1029 (abstract)